NCT01676662

Brief Summary

The Solace European Confirmatory (SOLECT) Trial is designed to determine whether the Solace Bladder Control System is safe and effective for the treatment of Stress Urinary Incontinence (SUI) in adult females.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2012

Longer than P75 for not_applicable

Geographic Reach
3 countries

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 23, 2012

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 31, 2012

Completed
1 day until next milestone

Study Start

First participant enrolled

September 1, 2012

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
2.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2017

Completed
Last Updated

June 23, 2017

Status Verified

June 1, 2017

Enrollment Period

1.7 years

First QC Date

August 23, 2012

Last Update Submit

June 22, 2017

Conditions

Keywords

Urinary IncontinenceUrinary Incontinence, StressUrination DisordersUrologic DiseasesUrological ManifestationsSigns and Symptoms

Outcome Measures

Primary Outcomes (1)

  • Improvement in quality of life as assessed by pad weight tests assessments and questionnaires

    Comparison of increases in pad weight test and patient reported outcomes on questionnaires.

    3 Months

Secondary Outcomes (2)

  • Incidence of treatment-related adverse events

    3 Months

  • Severity of treatment-related adverse events

    3 Months

Other Outcomes (3)

  • Incidence of all adverse events

    36 Months

  • Improvement in quality of life in all patients assessed with pad weight tests and questionnaires

    36 Months

  • Severity of all adverse events

    36 Months

Study Arms (2)

Treatment on Day 0

EXPERIMENTAL

Subjects who are treated with the Solace Bladder Control System upon entry into the trial.

Device: Solace Bladder Control System

Sham Treatment on Day 0

SHAM COMPARATOR

Patients who undergo a sham procedure upon entry into the trial, with treatment with the Solace Bladder Control System at 3 months after the sham procedure.

Device: Solace Bladder Control SystemDevice: Solace Sham Treatment

Interventions

Subjects may undergo treatment every 12 months until study completion.

Sham Treatment on Day 0Treatment on Day 0

Sham procedure that resembles treatment with the Solace Bladder Control System

Sham Treatment on Day 0

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female 18 years of age or older with stress urinary incontinence (SUI)
  • Experienced SUI for at least 12 months and attempted and failed prior noninvasive treatment
  • Willing to undergo cystoscopic procedures required and 36 month follow-up
  • On stable medication for a minimum of 3 months
  • Free of local genital skin infection
  • Positive Pad Weight Test
  • Free of impassable urethral strictures, trauma or necrosis

You may not qualify if:

  • Pregnant or planning to become pregnant during the study period
  • Non-ambulatory or bedridden or physically unable to complete test exercises
  • Morbidly obese (defined as BMI ≥ 40 kg/m2)
  • Bladder infection (including bladder inflammation or edema) or UTI within 3 months
  • History of recurrent urinary tract infections
  • Prior surgical procedure for incontinence within the past 6 months
  • Is taking medications for urinary incontinence other than anticholinergics
  • History of kidney stones
  • Has a prosthetic heart valve
  • Unable to tolerate any form of antibiotic
  • Taking anticoagulation therapy, other than aspirin
  • Has urinary incontinence due to Intrinsic Sphincter Deficiency (ISD)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

University of Antwerp Hospital (Universitair Ziekenhuis Antwerpen)

Antwerp, Edegem, 2650, Belgium

Location

UZ Brussel

Brussels, B-1090, Belgium

Location

UZ Gent

Ghent, Belgium

Location

University of Naples (Università Degli Studi Di Napoli "Federico II" )

Naples (Napoli), 80131, Italy

Location

Universita Campus Bio-medico di Roma

Rome, Italy

Location

Catharina Ziekenhuis

Eindhoven, Netherlands

Location

Maastricht University Medical Center

Maastricht, 6229 HX, Netherlands

Location

Related Publications (1)

  • Wyndaele JJ, De Wachter S, Tommaselli GA, Angioli R, de Wildt MJ, Everaert KC, Michielsen DP, Van Koeveringe GA. A randomized, controlled clinical trial of an intravesical pressure-attenuation balloon system for the treatment of stress urinary incontinence in females. Neurourol Urodyn. 2016 Feb;35(2):252-9. doi: 10.1002/nau.22708. Epub 2015 Jan 16.

MeSH Terms

Conditions

Urinary Incontinence, StressUrinary IncontinenceUrination DisordersUrologic DiseasesUrological ManifestationsSigns and Symptoms

Condition Hierarchy (Ancestors)

Female Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Giovanni Tommaselli, M.D.

    University of Naples

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 23, 2012

First Posted

August 31, 2012

Study Start

September 1, 2012

Primary Completion

June 1, 2014

Study Completion

January 1, 2017

Last Updated

June 23, 2017

Record last verified: 2017-06

Data Sharing

IPD Sharing
Will not share

Pending publication of results

Locations